Powered by the Evidence-based Practice Centers
SHARE:
FacebookTwitterFacebookPrintShare

Efficacy and Comparative Effectiveness of Off-Label Use of Atypical Antipsychotics

Systematic Review ARCHIVED Jan 17, 2007

Documents

Archived: This report has been updated.

People using assistive technology may not be able to fully access information in these files. For additional assistance, please contact us.

Excerpt

Aripiprazole, olanzapine, quetiapine, risperidone, and ziprasidone are atypical antipsychotics approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia and bipolar disorder. These drugs have been studied for off-label use in the following conditions: dementia and severe geriatric agitation, depression, obsessive-compulsive disorder, posttraumatic stress disorder, and personality disorders. The atypicals have also been studied for the management of Tourette's syndrome and autism in children. The purpose of this report is to review the scientific evidence on the safety and effectiveness of such off-label uses.

Project Timeline

Efficacy and Comparative Effectiveness of Off-Label Use of Atypical Antipsychotics

Jan 1, 2005
Topic Initiated
Jan 17, 2007
Systematic Review Archived
Page last reviewed December 2019
Page originally created November 2017

Internet Citation: Systematic Review: Efficacy and Comparative Effectiveness of Off-Label Use of Atypical Antipsychotics. Content last reviewed December 2019. Effective Health Care Program, Agency for Healthcare Research and Quality, Rockville, MD.
https://effectivehealthcare.ahrq.gov/products/atypical-antipsychotics-off-label/research

Select to copy citation